PATENT CLAIM ANALYSIS

Application Number: 15978695
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["530", "388220"]

Abstract:
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Claim (Index 10):
The antibody of  claim 1 , wherein the antibody exhibits anti-tumor activity.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 93.0
- Lexical Diversity: 1.3
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15802093', '14736966', '14194797', '14076214', '15323153']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8275084525927169
- 35 USC 102 Novelty (BERT): 0.6461903533140679
- Combined Prediction Score: 0.809376642664852
- Mean Citation Score: 653.73565
- Max Citation Score: 725.198
- Similarity Product: 543.8464136711359

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test